Coronavirus disease 2019 in a psoriatic patient with concomitant chronic obstructive pulmonary disease under treatment with risankizumab

Dermatol Ther. 2020 Nov;33(6):e14186. doi: 10.1111/dth.14186. Epub 2020 Sep 8.

Authors

Norbert Kiss¹, Kende Lőrincz¹, Márta Medvecz¹, Luca Fésűs¹, Péter Csuha², Zsolt Hermányi², Norbert Miklós Wikonkál¹

Affiliations

¹ Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary.
² 3rd Department of Internal Medicine, Bajcsy-Zsilinszky Hospital, Budapest, Hungary.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Antiviral Agents / therapeutic use
Biological Products / adverse effects
Biological Products / therapeutic use*
COVID-19 / diagnosis
COVID-19 / immunology
COVID-19 / virology*
COVID-19 Drug Treatment
Dermatologic Agents / adverse effects
Dermatologic Agents / therapeutic use*
Host-Pathogen Interactions
Humans
Male
Psoriasis / diagnosis
Psoriasis / drug therapy*
Psoriasis / immunology
Pulmonary Disease, Chronic Obstructive* / diagnosis
Pulmonary Disease, Chronic Obstructive* / immunology
SARS-CoV-2 / drug effects
SARS-CoV-2 / immunology
SARS-CoV-2 / pathogenicity*
Treatment Outcome

Substances

Antibodies, Monoclonal
Antiviral Agents
Biological Products
Dermatologic Agents
risankizumab